ATLANTA — It’s CAR-T Sunday at the American Society of Hematology’s annual meeting, where researchers representing Gilead Sciences (GILD), Novartis (NVS) and Bluebird Bio (BLUE) are addressing the assembled media horde.
Here’s your quick summary: The complete remission rate to Gilead’s Yescarta remains durable after more than one year of follow up. There are no surprises in the details from the previously announced (and positive) JULIET study of Novartis’ Kymriah in aggressive lymphoma. And the updated overall response to Bluebird’s BB2121 in multiple myeloma is now one patient short of 100 percent. No longer perfect, but very close.
About the Author Reprints
Adam check out IMUC press release!
Huge News!
Today, Celgene and Bluebird Bio, both stocks raise on their announcement in ASH. http://alph.st/bd17bb56